Article
A multi-centre, phase IV study to evaluate the steady-state plasma concentration and serum bactericidal activity of a generic teicoplanin preparation
DOI:
10.1080/23120053.2015.1076165
Author(s):
Oppel GreeffDepartment of Pharmacology, School of Medicine, Faculty of Health Sciences, South Africa, Jacob van TonderDepartment of Pharmacology, School of Medicine, Faculty of Health Sciences, South Africa, Duncan CromartyDepartment of Pharmacology, School of Medicine, Faculty of Health Sciences, South Africa, Warren LowmanDepartment of Clinical Microbiology and Infectious Diseases, School of Pathology, South Africa, Piet BeckerFaculty of Health Sciences, South Africa, Margo NellDepartment of Pharmacology, School of Medicine, Faculty of Health Sciences, South Africa,
Abstract
Introduction: Teicoplanin is an effective treatment option against methicillin-resistant, Gram-positive bacteria, like Staphylococcus aureus. It is a glycopeptide antibiotic, produced through microbial fermentation, a process resulting in variations in the N-acyl side chain. Concerns that these variations may affect the pharmacokinetic profile and the clinical efficacy of generic teicoplanin preparations have been raised.
Get new issue alerts for Southern African Journal of Infectious Diseases
